U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Vaccines, Blood & Biologics
  3. Blood & Blood Products
  4. Approved Blood Products
  1. Blood & Blood Products

The following products are regulated as Biologics License Applications (BLAs):  Fractionated Plasma Products (Alpha-1-Proteinase Inhibitor, Antihemophilic Factor, Antithrombin, C1 Esterase Inhibitor, Coagulation Factors, Fibrin, Fibrinogen, Immune Globulins, Protein C, Thrombin) and Blood Donor Screening Tests for Infectious Diseases and Blood Grouping and Phenotyping.

The following products are regulated as New Drug Applications (NDAS): Solutions used in the collection of blood and plasma donations.

The following products are regulated as Premarket Approvals (PMAs): Devices associated with blood donor testing.

The following products are regulated as 510(k)s: Devices used by the blood banking industry including blood establishment computer software, transfer devices, collection systems, separators, culture bottles, fluid warmers, etc.


Licensed Products (BLAs)

New Drug Applications (NDAs)

Premarket Approvals (PMAs)

Substantially Equivalent 510(k) Device Information

Development & Approval Process


Sub-Topic Paragraphs

Follow CBER

Division of Communication and Consumer Affairs
Office of Communication, Outreach and Development
Center for Biologics Evaluation and Research
Food and Drug Administration
10903 New Hampshire Ave WO71-3103
Silver Spring, MD 20993-0002

ocod@fda.hhs.gov

(800) 835-4709
(240) 402-8010

For Updates on Twitter, follow @fdacber


Subscribe for CBER Updates

Get e-mail updates on What's New at CBER!

Back to Top